Merck KGaA reports response data for tepotinib in c-MET mutant NSCLC

Merck KGaA (Xetra:MRK) said 500 mg once-daily tepotinib (MSC2167119J) led to a partial response rate of 42.9% and a stable disease rate

Read the full 221 word article

User Sign In